CDT Equity Inc. (NASDAQ:CDT) Short Interest Update

CDT Equity Inc. (NASDAQ:CDT) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 53,538 shares, an increase of 70.8% from the May 14th total of 31,350 shares. Currently, 1.2% of the company’s shares are short sold. Based on an average daily volume of 5,554,158 shares, the short-interest ratio is presently 0.0 days.

CDT Equity Stock Performance

NASDAQ:CDT traded up $0.03 during trading on Monday, reaching $0.73. The company’s stock had a trading volume of 61,473 shares, compared to its average volume of 537,360. The firm has a market cap of $3.53 million, a price-to-earnings ratio of 0.00 and a beta of 1.44. The firm has a 50 day moving average of $2.29 and a 200-day moving average of $19.60. CDT Equity has a 12 month low of $0.67 and a 12 month high of $610.00.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.